UPDATED: AstraZeneca pays $50M to partner ahead on Amgen antibodies FierceBiotech The most advanced system in the lot is 827, brodalumab, which is on the threshold of Phase III for disease of the skin and in mid-stage studies on psoriatic arthritis and asthma. The rest of the antibodies in the deal are in state of matter Ia or Ib studies. AstraZeneca Spreads The burden With Amgen Development Deal Seeking Alpha Big pharmaceutical company Buys Access to This Promising Biotech Pipeline DailyFinance AstraZeneca And Amgen inform Collaboration To Jointly Develop BioResearch Online (press release) Pharma Times - Bizjournals.com (blog) all 16 tidings articles » Link To Article
No comments:
Post a Comment